Corbus (NASDAQ: CRBP) director sells 2,412 shares under 10b5-1 plan

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings director Anne Altmeyer sold 2,412 shares of common stock in an open-market transaction at a weighted average price of $7.9137 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2026.

These shares were sold in multiple trades at prices ranging from $7.71 to $7.97. After the sale, Altmeyer directly holds 7,579 shares of common stock, which includes 3,800 unvested restricted stock units that remain subject to the grant’s vesting schedule.

Insights

Equity Compensation & Governance Analyst

Small, pre-planned director sale with substantial equity stake remaining.

Director Anne Altmeyer executed an open-market sale of 2,412 Corbus Pharmaceuticals shares at a weighted average price of $7.9137. The transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2026, indicating it was scheduled in advance.

Following the sale, she holds 7,579 shares directly, including 3,800 unvested RSUs that continue vesting under the prior grant terms. The filing does not show derivative option holdings, suggesting the key remaining exposure is common stock and RSUs from this snapshot.

This single net-sell transaction is relatively modest in size and structured through a trading plan, which typically points to routine portfolio or liquidity management rather than a change in outlook. Future company filings may provide additional context on any subsequent equity awards or transactions.

Insider Trade Summary 10b5-1

Net Seller: 2,412 shares ($19,088)

Net Sell 1 txn

Insider Altmeyer Anne

Role null

Sold 2,412 shs ($19K)

Type	Security	Shares	Price	Value
Sale	Common Stock, par value $0.0001 per share	2,412	$7.9137	$19K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 7,579 shares (Direct, null)

Footnotes (1)

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported.

Key Figures

Shares sold: 2,412 shares Weighted average sale price: $7.9137 per share Sale price range: $7.71 to $7.97 per share +3 more

6 metrics

Shares sold 2,412 shares Open-market sale on June 10, 2026

Weighted average sale price $7.9137 per share Common stock sale

Sale price range $7.71 to $7.97 per share Multiple transaction prices

Shares held after transaction 7,579 shares Direct ownership following sale

Unvested RSUs included 3,800 RSUs Subject to vesting schedule

Net buy/sell direction Net sale of 2,412 shares Single reported transaction

Key Terms

Rule 10b5-1 trading plan, weighted average price, restricted stock units, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

restricted stock units financial

"This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock, par value $0.0001 per share financial

"security_title: Common Stock, par value $0.0001 per share"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/11/2026 - 04:31 PM Accepted by SEC EDGAR 06/11/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altmeyer Anne

(Last) (First) (Middle)

C/O CORBUS PHARMACEUTICALS HOLDINGS, INC

500 RIVER RIDGE DRIVE

(Street)

NORWOOD MASSACHUSETTS 02062

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	06/10/2026		S(1)		2,412	D	$7.9137(2)	7,579(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported.

	/s/ Meghan Houghton, attorney-in-fact for Anne Altmeyer	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Corbus Pharmaceuticals (CRBP) director Anne Altmeyer do in this Form 4?

Director Anne Altmeyer sold 2,412 shares of Corbus Pharmaceuticals common stock in an open-market transaction. The weighted average sale price was $7.9137 per share, and the transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted earlier in 2026.

At what prices were the CRBP shares sold by director Anne Altmeyer?

The reported weighted average sale price was $7.9137 per CRBP share. According to the filing, individual trades occurred at prices ranging from $7.71 to $7.97, with the director offering to provide detailed trade breakdowns to interested parties upon request.

How many Corbus Pharmaceuticals (CRBP) shares does Anne Altmeyer hold after this sale?

After the reported sale, Anne Altmeyer directly holds 7,579 shares of Corbus Pharmaceuticals common stock. This figure includes 3,800 unvested restricted stock units, which remain subject to the existing vesting schedule disclosed in prior compensation-related disclosures.

Was the CRBP director’s stock sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Anne Altmeyer on March 11, 2026. Such plans are pre-arranged trading programs designed to allow insiders to sell shares on a scheduled basis.

Does the Form 4 show any derivative or option exercises for CRBP by Anne Altmeyer?

No derivative or option exercises are reported in this Form 4. The filing discloses only a non-derivative open-market sale of common stock, with remaining holdings consisting of common shares and 3,800 unvested restricted stock units subject to vesting.

What is the significance of the unvested RSUs reported for CRBP director Anne Altmeyer?

The filing notes that Anne Altmeyer’s holdings include 3,800 unvested RSUs. These restricted stock units represent additional future share ownership, contingent on continued service or achievement of vesting conditions outlined in the original grant documentation.